Sagimet Biosciences Files 8-K on Financials
Ticker: SGMT · Form: 8-K · Filed: Aug 13, 2025 · CIK: 1400118
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
Sagimet Biosciences dropped an 8-K detailing its financials - check it for the latest on their operations.
AI Summary
Sagimet Biosciences Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements. The company, formerly known as 3-V Biosciences, Inc., is incorporated in Delaware and headquartered in San Mateo, California.
Why It Matters
This 8-K filing provides crucial updates on Sagimet Biosciences' financial health and operational status, which is important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting financial results and does not indicate any unusual or significant negative events.
Key Players & Entities
- Sagimet Biosciences Inc. (company) — Registrant
- 3-V Biosciences, Inc. (company) — Former company name
- August 13, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- San Mateo, California (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing by Sagimet Biosciences Inc.?
The primary purpose of this 8-K filing is to report on Sagimet Biosciences Inc.'s results of operations and financial condition, along with Regulation FD disclosures and financial statements.
When was this 8-K report filed?
This 8-K report was filed on August 13, 2025.
What was Sagimet Biosciences Inc. formerly known as?
Sagimet Biosciences Inc. was formerly known as 3-V Biosciences, Inc.
Where are Sagimet Biosciences Inc.'s principal executive offices located?
Sagimet Biosciences Inc.'s principal executive offices are located at 155 Bovet Road, Suite 303, San Mateo, California 94402.
What is the Commission File Number for Sagimet Biosciences Inc.?
The Commission File Number for Sagimet Biosciences Inc. is 001-41742.
Filing Stats: 675 words · 3 min read · ~2 pages · Grade level 10 · Accepted 2025-08-13 07:36:20
Key Financial Figures
- $0.0001 — ich registered Series A Common Stock, $0.0001 par value per share SGMT The Nasdaq G
Filing Documents
- tm2523275d1_8k.htm (8-K) — 29KB
- tm2523275d1_ex99-1.htm (EX-99.1) — 70KB
- tm2523275d1_ex99-2.htm (EX-99.2) — 70KB
- tm2523275d1_ex99-1img001.jpg (GRAPHIC) — 16KB
- tm2523275d1_ex99-2img001.jpg (GRAPHIC) — 163KB
- tm2523275d1_ex99-2img002.jpg (GRAPHIC) — 375KB
- tm2523275d1_ex99-2img003.jpg (GRAPHIC) — 201KB
- tm2523275d1_ex99-2img004.jpg (GRAPHIC) — 164KB
- tm2523275d1_ex99-2img005.jpg (GRAPHIC) — 151KB
- tm2523275d1_ex99-2img006.jpg (GRAPHIC) — 168KB
- tm2523275d1_ex99-2img007.jpg (GRAPHIC) — 131KB
- tm2523275d1_ex99-2img008.jpg (GRAPHIC) — 162KB
- tm2523275d1_ex99-2img009.jpg (GRAPHIC) — 145KB
- tm2523275d1_ex99-2img010.jpg (GRAPHIC) — 161KB
- tm2523275d1_ex99-2img011.jpg (GRAPHIC) — 111KB
- tm2523275d1_ex99-2img012.jpg (GRAPHIC) — 173KB
- tm2523275d1_ex99-2img013.jpg (GRAPHIC) — 180KB
- tm2523275d1_ex99-2img014.jpg (GRAPHIC) — 136KB
- tm2523275d1_ex99-2img015.jpg (GRAPHIC) — 125KB
- tm2523275d1_ex99-2img016.jpg (GRAPHIC) — 169KB
- tm2523275d1_ex99-2img017.jpg (GRAPHIC) — 194KB
- tm2523275d1_ex99-2img018.jpg (GRAPHIC) — 202KB
- tm2523275d1_ex99-2img019.jpg (GRAPHIC) — 209KB
- tm2523275d1_ex99-2img020.jpg (GRAPHIC) — 158KB
- tm2523275d1_ex99-2img021.jpg (GRAPHIC) — 203KB
- tm2523275d1_ex99-2img022.jpg (GRAPHIC) — 134KB
- tm2523275d1_ex99-2img023.jpg (GRAPHIC) — 125KB
- tm2523275d1_ex99-2img024.jpg (GRAPHIC) — 151KB
- tm2523275d1_ex99-2img025.jpg (GRAPHIC) — 136KB
- tm2523275d1_ex99-2img026.jpg (GRAPHIC) — 194KB
- tm2523275d1_ex99-2img027.jpg (GRAPHIC) — 101KB
- tm2523275d1_ex99-2img028.jpg (GRAPHIC) — 181KB
- tm2523275d1_ex99-2img029.jpg (GRAPHIC) — 140KB
- tm2523275d1_ex99-2img030.jpg (GRAPHIC) — 239KB
- tm2523275d1_ex99-2img031.jpg (GRAPHIC) — 206KB
- tm2523275d1_ex99-2img032.jpg (GRAPHIC) — 156KB
- tm2523275d1_ex99-2img033.jpg (GRAPHIC) — 212KB
- tm2523275d1_ex99-2img034.jpg (GRAPHIC) — 107KB
- tm2523275d1_ex99-2img035.jpg (GRAPHIC) — 95KB
- tm2523275d1_ex99-2img036.jpg (GRAPHIC) — 171KB
- tm2523275d1_ex99-2img037.jpg (GRAPHIC) — 173KB
- tm2523275d1_ex99-2img038.jpg (GRAPHIC) — 175KB
- tm2523275d1_ex99-2img039.jpg (GRAPHIC) — 191KB
- tm2523275d1_ex99-2img040.jpg (GRAPHIC) — 168KB
- tm2523275d1_ex99-2img041.jpg (GRAPHIC) — 215KB
- tm2523275d1_ex99-2img042.jpg (GRAPHIC) — 160KB
- tm2523275d1_ex99-2img043.jpg (GRAPHIC) — 188KB
- tm2523275d1_ex99-2img044.jpg (GRAPHIC) — 178KB
- tm2523275d1_ex99-2img045.jpg (GRAPHIC) — 173KB
- tm2523275d1_ex99-2img046.jpg (GRAPHIC) — 109KB
- tm2523275d1_ex99-2img047.jpg (GRAPHIC) — 98KB
- tm2523275d1_ex99-2img048.jpg (GRAPHIC) — 196KB
- tm2523275d1_ex99-2img049.jpg (GRAPHIC) — 177KB
- tm2523275d1_ex99-2img050.jpg (GRAPHIC) — 164KB
- 0001104659-25-077200.txt ( ) — 11958KB
- sgmt-20250813.xsd (EX-101.SCH) — 3KB
- sgmt-20250813_lab.xml (EX-101.LAB) — 33KB
- sgmt-20250813_pre.xml (EX-101.PRE) — 22KB
- tm2523275d1_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 99.1 Press Release of Sagimet Biosciences Inc., dated August 13, 2025. 99.2 Investor Presentation of Sagimet Biosciences Inc., dated August 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: August 13, 2025 By: /s/ David Happel David Happel Chief Executive Officer